# Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer

## TL;DR

This paper reviews recent innovations in cancer immunotherapy, focusing on strategies like CAR-T cells and immune checkpoint inhibitors to improve cancer treatment.

## Contribution

The paper provides a comprehensive analysis of emerging immunotherapeutic strategies and their potential for personalized cancer treatment.

## Key findings

- CAR-T cells show clinical success in treating blood cancers.
- Immune checkpoint inhibitors are expanding in application to solid tumors.
- Bispecific antibodies are evolving to better recruit immune effectors.

## Abstract

Cancer immunotherapy has emerged as a transformative approach in oncology, offering alternatives beyond traditional treatments. This narrative review focuses on major innovations, including adoptive cell therapy (ACT), chimeric antigen receptor T-cells (CAR-T), T-cell receptor (TCR) engineering, monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs). The central aim of this article is to analyze how these technologies improve antitumor responses and help overcome resistance in hematologic and solid tumors. This narrative review combines the latest findings from clinical and preclinical studies to highlight therapeutic potentials and challenges. Key observations include the clinical success of CAR-T cells in treating blood cancers, the expanding application of ICIs in solid tumors, and the evolving structure-function relationship of BsAbs in recruiting immune effectors. This paper concludes by evaluating the current limitations of these immunotherapeutic strategies and discusses future directions for integrating them into personalized cancer therapy.